Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Leap Therapeutics logo — company profile

Leap Therapeutics

Founded 2011 United States Cambridge, United States 51 employees Post-IPO Equity Total: $266.50M Biotechnology, Life Sciences

General Information

Company Name Leap Therapeutics
Founded Year 2011
Location United States Cambridge, United States
Founders / Decision Makers
Team member
Employees 51
Industries Biotechnology, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Leap Therapeutics. To contact Leap Therapeutics, visit leaptx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Leap Therapeutics compare?

A PDF of Leap Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Leap Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Leap Therapeutics

### Leap Therapeutics: Acquiring Novel Therapeutics at the Leading Edge of Cancer Research

Leap Therapeutics is a clinical-stage biopharmaceutical company that focuses on acquiring and developing novel therapeutics at the forefront of cancer research. Founded in 2011 and headquartered in the United States, the company has attracted significant attention from notable investors.

Notably, Gilead Sciences, Laurion Capital, Rock Springs Capital, Samsara BioCapital, and 683 CAPITAL have participated in its latest $40.00M Post-IPO Equity investment on 10 April 2024.

With a clear focus on the biotechnology industry, Leap Therapeutics has positioned itself as an intriguing investment opportunity in the oncology therapeutics space. For more information, interested parties can visit the company's website at www.leaptx.com or access public filings with the SEC via EDGAR or investors.leaptx.com.

Business keywords: biopharmaceutical, clinical-stage, cancer research, therapeutics, oncology, drug development, clinical trials, cancer therapy, innovation

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $40.00M 5
Gilead Sciences Laurion Capital Rock Springs Capital
Gilead Sciences, Laurion Capital +3
10 Apr 2024
Post IPO Equity $90.00M -
22 Sep 2021
Post IPO Equity $45.00M -
18 Jun 2020
Post IPO Equity $27.00M 1
BeiGene
BeiGene
03 Jan 2020
Post IPO Equity $21.00M 1
Lincoln Park Capital Fund
Lincoln Park Capital Fund
11 Jul 2019
Post IPO Equity $11.50M -
01 Feb 2019
Post IPO Equity $14.00M -
23 Mar 2018
Post IPO Equity $18.00M 1
Eli Lilly & Company Foundation
15 Nov 2017
Venture Round Undisclosed 1
HealthCare Ventures
HealthCare Ventures
01 Jan 2016
Seed Round Undisclosed 1
Torrey Pines Investment
Torrey Pines Investment
28 Feb 2015

Leap Therapeutics Alternatives & Competitors

View All Alternatives
Leap Therapeutics vs
TransThera | 药捷安康
TransThera | 药捷安康

Transformative Therapy! Innovation for global patients.

Series D
19 employees
Biotechnology, Life Sciences
Compare Leap Therapeutics vs TransThera | 药捷安康
Leap Therapeutics vs
Eikon Therapeutics
Eikon Therapeutics United States

Eikon is a late-stage clinical biopharmaceutical company dedicated to inventing and developing break...

Series D
429 employees
Biotechnology, Health Care
Compare Leap Therapeutics vs Eikon Therapeutics
Leap Therapeutics vs
Avelos Therapeutics
Avelos Therapeutics Korea South

Strive for a Better Tomorrow.

Series B
9 employees
Biotechnology, Life Sciences
View all alternatives

FAQ About Leap Therapeutics

Leap Therapeutics (NASDAQ: LPTX) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via ED...
Leap Therapeutics was founded in 2011.
Leap Therapeutics is headquartered in Cambridge, United States.
Leap Therapeutics operates in Biotechnology and Life Sciences. Its work centres on biopharmaceutical, clinical-stage, cancer research and therapeutics.
Leap Therapeutics has approximately 51 employees.
Leap Therapeutics has completed 10 funding rounds, raising a total of $266.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Leap Therapeutics include TransThera | 药捷安康, Eikon Therapeutics, Avelos Therapeutics, Carisma Therapeutics, Aadi Bioscience, Inc. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Leap Therapeutics and TransThera | 药捷安康 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Leap Therapeutics, https://bouncewatch.com/company/leap-therapeutics, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout